Parmax Pharma Ltd vs Vivo Bio Tech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Parmax Pharma Ltd is ₹ 32.1 as of 12 May 15:30 . The P/E Ratio of Parmax Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Vivo Bio Tech Ltd changed from 11.3 on March 2021 to 8 on March 2025 . This represents a CAGR of -6.67% over 5 years The Market Cap of Parmax Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Vivo Bio Tech Ltd changed from ₹ 64.28 crore on March 2021 to ₹ 57.3 crore on March 2025 . This represents a CAGR of -2.27% over 5 years The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Vivo Bio Tech Ltd for the Dec '25 is ₹ 13.65 crore as compare to the Sep '25 revenue of ₹ 13.24 crore. This represent the growth of 3.1% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Vivo Bio Tech Ltd for the Dec '25 is ₹ 5.63 crore as compare to the Sep '25 ebitda of ₹ 5.55 crore. This represent the growth of 1.44% The net profit of Parmax Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Vivo Bio Tech Ltd changed from ₹ 0.17 crore to ₹ 1.25 crore over 7 quarters. This represents a CAGR of 212.69% The Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vivo Bio Tech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

About Vivo Bio Tech Ltd

Vivo Bio Tech Limited, established in February, 1987 is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines.
The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies, Genotoxicity screening, Analytical services etc.
Their experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. The Company stands as a premier and primary provider of SPF lab animals in India.
It holds the distinction of being the largest breeder and distributor of rodent models, in addition to offering custom rodent models and stem cell products through Cyagen Biosciences.

FAQs for the comparison of Parmax Pharma Ltd and Vivo Bio Tech Ltd

Which company has a larger market capitalization, Parmax Pharma Ltd or Vivo Bio Tech Ltd?

Market cap of Parmax Pharma Ltd is 12 Cr while Market cap of Vivo Bio Tech Ltd is 62 Cr

What are the key factors driving the stock performance of Parmax Pharma Ltd and Vivo Bio Tech Ltd?

The stock performance of Parmax Pharma Ltd and Vivo Bio Tech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Parmax Pharma Ltd and Vivo Bio Tech Ltd?

As of May 12, 2026, the Parmax Pharma Ltd stock price is INR ₹32.74. On the other hand, Vivo Bio Tech Ltd stock price is INR ₹28.27.

How do dividend payouts of Parmax Pharma Ltd and Vivo Bio Tech Ltd compare?

To compare the dividend payouts of Parmax Pharma Ltd and Vivo Bio Tech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.